DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression

Published:2022-12-29 Issue: Volume: Page:
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Kong Tim^ORCID,Laranjeira Angelo B. A.,Yang Kangning^ORCID,Fisher Daniel A. C.,Yu LaYow,Poittevin De La Frégonnière Laure,Wang Anthony Z.,Ruzinova Marianna B.,Fowles Jared S.,Fulbright Mary C.,Cox Maggie J.,Celik Hamza,Challen Grant A.,Huang Sidong^ORCID,Oh Stephen T.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Gouvernement du Canada | Canadian Institutes of Health Research

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Leukemia and Lymphoma Society

MPN Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s43018-022-00486-8.pdf

Reference71 articles.

1. Levine, R. L. & Gilliland, D. G. Myeloproliferative disorders. Blood 112, 2190–2198 (2008).

2. Oh, S. T. & Gotlib, J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev. Hematol. 3, 323–337 (2010).

3. Zoi, K. & Cross, N. C. Genomics of myeloproliferative neoplasms. J. Clin. Oncol. 35, 947–954 (2017).

4. Tefferi, A. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 342, 1255–1265 (2000).

5. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787–798 (2012).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era;Blood Advances;2024-06-28

2. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer;EMBO Molecular Medicine;2024-06-17

3. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms;Blood;2024-06-06

4. Functional Role of DUSP6 in the EGFR-mediated Progression of Head and Neck Squamous Cell Carcinoma;Anticancer Research;2024-05-31

5. Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms;Experimental Hematology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3